Pulmonary arterial hypertension associated with tetralogy of Fallot

Jun Yasuhara, Hiroyuki Yamagishi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is a common postoperative complication in patients with congenital heart disease (CHD). Although the recent clinical classification of pulmonary hypertension divided PAH associated with CHD (PAH–CHD) into several subclasses, the anatomical and hemodynamic features of postoperative PAH–CHD vary enormously. Therefore, it is still difficult to obtain clinical evidence supporting the indication of pulmonary vasodilators for PAH–CHD. We often encounter patients with PAH occurring after surgical treatment of tetralogy of Fallot (TOF), especially patients with major aortopulmonary collateral arteries (MAPCAs). PAH might be caused by pulmonary agenesis, hypoplasia and/or thrombosis, inadequate closure of the ventricular septal defect, relief of the pulmonic stenosis, or an excessively large prior systemic-to-pulmonary shunt. Moreover, patients with TOF and MAPCAs who are diagnosed as inoperable because of the presence of PAH show similar hemodynamic and clinical features to patients with Eisenmenger syndrome. The MAPCAs in these patients usually show hypoplastic and abnormal arborization. Based on our experience, we believe that PAH-targeted therapies are effective in some patients with PAH occurring after surgical treatment of TOF and MAPCAs, especially as an adjunct to percutaneous pulmonary angioplasty. To help classify patients with PAH associated with TOF, especially with MAPCAs, we propose several new subclassifications: “PAH due to hypoplastic pulmonary arterial beds”, “PAH due to abnormal pulmonary arborization”, or “segmental PAH associated with CHD.” A multicenter registry of patients using a unified protocol is essential to explore the indications and efficacy of pulmonary vasodilators for postoperative PAH–CHD.

Original languageEnglish
Pages (from-to)S17-S21
JournalInternational Heart Journal
Volume56
Publication statusPublished - 2015 Mar 19

Fingerprint

Tetralogy of Fallot
Pulmonary Hypertension
Arteries
Lung
Heart Diseases
Vasodilator Agents
Hemodynamics
Eisenmenger Complex
Pulmonary Valve Stenosis
Ventricular Heart Septal Defects
Angioplasty
Registries
Thrombosis
Therapeutics

Keywords

  • Major aortopulmonary collateral artery
  • Percutaneous pulmonary angioplasty
  • Pulmonary arterial bed
  • Pulmonary vasodilator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Pulmonary arterial hypertension associated with tetralogy of Fallot. / Yasuhara, Jun; Yamagishi, Hiroyuki.

In: International Heart Journal, Vol. 56, 19.03.2015, p. S17-S21.

Research output: Contribution to journalArticle

@article{739c955202fe408891f881e73a979fc6,
title = "Pulmonary arterial hypertension associated with tetralogy of Fallot",
abstract = "Pulmonary arterial hypertension (PAH) is a common postoperative complication in patients with congenital heart disease (CHD). Although the recent clinical classification of pulmonary hypertension divided PAH associated with CHD (PAH–CHD) into several subclasses, the anatomical and hemodynamic features of postoperative PAH–CHD vary enormously. Therefore, it is still difficult to obtain clinical evidence supporting the indication of pulmonary vasodilators for PAH–CHD. We often encounter patients with PAH occurring after surgical treatment of tetralogy of Fallot (TOF), especially patients with major aortopulmonary collateral arteries (MAPCAs). PAH might be caused by pulmonary agenesis, hypoplasia and/or thrombosis, inadequate closure of the ventricular septal defect, relief of the pulmonic stenosis, or an excessively large prior systemic-to-pulmonary shunt. Moreover, patients with TOF and MAPCAs who are diagnosed as inoperable because of the presence of PAH show similar hemodynamic and clinical features to patients with Eisenmenger syndrome. The MAPCAs in these patients usually show hypoplastic and abnormal arborization. Based on our experience, we believe that PAH-targeted therapies are effective in some patients with PAH occurring after surgical treatment of TOF and MAPCAs, especially as an adjunct to percutaneous pulmonary angioplasty. To help classify patients with PAH associated with TOF, especially with MAPCAs, we propose several new subclassifications: “PAH due to hypoplastic pulmonary arterial beds”, “PAH due to abnormal pulmonary arborization”, or “segmental PAH associated with CHD.” A multicenter registry of patients using a unified protocol is essential to explore the indications and efficacy of pulmonary vasodilators for postoperative PAH–CHD.",
keywords = "Major aortopulmonary collateral artery, Percutaneous pulmonary angioplasty, Pulmonary arterial bed, Pulmonary vasodilator",
author = "Jun Yasuhara and Hiroyuki Yamagishi",
year = "2015",
month = "3",
day = "19",
language = "English",
volume = "56",
pages = "S17--S21",
journal = "International Heart Journal",
issn = "1349-2365",
publisher = "International Heart Journal Association",

}

TY - JOUR

T1 - Pulmonary arterial hypertension associated with tetralogy of Fallot

AU - Yasuhara, Jun

AU - Yamagishi, Hiroyuki

PY - 2015/3/19

Y1 - 2015/3/19

N2 - Pulmonary arterial hypertension (PAH) is a common postoperative complication in patients with congenital heart disease (CHD). Although the recent clinical classification of pulmonary hypertension divided PAH associated with CHD (PAH–CHD) into several subclasses, the anatomical and hemodynamic features of postoperative PAH–CHD vary enormously. Therefore, it is still difficult to obtain clinical evidence supporting the indication of pulmonary vasodilators for PAH–CHD. We often encounter patients with PAH occurring after surgical treatment of tetralogy of Fallot (TOF), especially patients with major aortopulmonary collateral arteries (MAPCAs). PAH might be caused by pulmonary agenesis, hypoplasia and/or thrombosis, inadequate closure of the ventricular septal defect, relief of the pulmonic stenosis, or an excessively large prior systemic-to-pulmonary shunt. Moreover, patients with TOF and MAPCAs who are diagnosed as inoperable because of the presence of PAH show similar hemodynamic and clinical features to patients with Eisenmenger syndrome. The MAPCAs in these patients usually show hypoplastic and abnormal arborization. Based on our experience, we believe that PAH-targeted therapies are effective in some patients with PAH occurring after surgical treatment of TOF and MAPCAs, especially as an adjunct to percutaneous pulmonary angioplasty. To help classify patients with PAH associated with TOF, especially with MAPCAs, we propose several new subclassifications: “PAH due to hypoplastic pulmonary arterial beds”, “PAH due to abnormal pulmonary arborization”, or “segmental PAH associated with CHD.” A multicenter registry of patients using a unified protocol is essential to explore the indications and efficacy of pulmonary vasodilators for postoperative PAH–CHD.

AB - Pulmonary arterial hypertension (PAH) is a common postoperative complication in patients with congenital heart disease (CHD). Although the recent clinical classification of pulmonary hypertension divided PAH associated with CHD (PAH–CHD) into several subclasses, the anatomical and hemodynamic features of postoperative PAH–CHD vary enormously. Therefore, it is still difficult to obtain clinical evidence supporting the indication of pulmonary vasodilators for PAH–CHD. We often encounter patients with PAH occurring after surgical treatment of tetralogy of Fallot (TOF), especially patients with major aortopulmonary collateral arteries (MAPCAs). PAH might be caused by pulmonary agenesis, hypoplasia and/or thrombosis, inadequate closure of the ventricular septal defect, relief of the pulmonic stenosis, or an excessively large prior systemic-to-pulmonary shunt. Moreover, patients with TOF and MAPCAs who are diagnosed as inoperable because of the presence of PAH show similar hemodynamic and clinical features to patients with Eisenmenger syndrome. The MAPCAs in these patients usually show hypoplastic and abnormal arborization. Based on our experience, we believe that PAH-targeted therapies are effective in some patients with PAH occurring after surgical treatment of TOF and MAPCAs, especially as an adjunct to percutaneous pulmonary angioplasty. To help classify patients with PAH associated with TOF, especially with MAPCAs, we propose several new subclassifications: “PAH due to hypoplastic pulmonary arterial beds”, “PAH due to abnormal pulmonary arborization”, or “segmental PAH associated with CHD.” A multicenter registry of patients using a unified protocol is essential to explore the indications and efficacy of pulmonary vasodilators for postoperative PAH–CHD.

KW - Major aortopulmonary collateral artery

KW - Percutaneous pulmonary angioplasty

KW - Pulmonary arterial bed

KW - Pulmonary vasodilator

UR - http://www.scopus.com/inward/record.url?scp=84929942836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929942836&partnerID=8YFLogxK

M3 - Article

C2 - 25787793

AN - SCOPUS:84929942836

VL - 56

SP - S17-S21

JO - International Heart Journal

JF - International Heart Journal

SN - 1349-2365

ER -